NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $0.0011 +0.00 (+10.00%) As of 12:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Telesis Bio Stock (NASDAQ:TBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Telesis Bio alerts:Sign Up Key Stats Today's Range$0.0011▼$0.001150-Day Range$0.00▼$0.0552-Week Range$0.00▼$0.15Volume217 shsAverage Volume1,429 shsMarket Capitalization$1.98 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Telesis Bio, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications. The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants. These agents are being evaluated both as monotherapies in solid tumors and in combination with checkpoint inhibitors, with the goal of converting immunologically “cold” tumors into “hot” ones that are more likely to respond to treatment. In parallel, Telesis Bio is exploring the use of its PRR agonists as adjuvants in therapeutic and prophylactic vaccines, aiming to improve antigen-specific immune activation. Founded in 2015 and headquartered in South San Francisco, California, Telesis Bio collaborates with leading academic institutions and biotechnology partners to accelerate its research and development efforts. The company is led by an experienced management team with expertise in immunology, molecular biology, and clinical development. Telesis Bio continues to expand its platform through strategic partnerships and preclinical studies, with the objective of delivering next-generation immunotherapies to patients in the United States and globally.AI Generated. May Contain Errors. Read More Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TBIO Stock News HeadlinesTelesis Bio, Inc. Common Stock (TBIO)May 14, 2026 | nasdaq.comTelesis Bio Inc.April 17, 2026 | barrons.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.July 23 at 1:00 AM | Base Camp Trading (Ad)Telesis Bio Inc (TBIO) Stock Forums - Investing.comJune 29, 2025 | investing.comTelesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene SynthesisMay 28, 2025 | finance.yahoo.comTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comTelesis Bio Shares Double After News of Beckman Coulter Life Sciences CollaborationSeptember 27, 2024 | marketwatch.comSee More Headlines TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $0.05 at the beginning of the year. Since then, TBIO shares have decreased by 97.8% and is now trading at $0.0011. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) announced its earnings results on Monday, November, 8th. The company reported ($6.12) EPS for the quarter, missing analysts' consensus estimates of ($5.04) by $1.08. The company had revenue of $2.79 million for the quarter, compared to analysts' expectations of $2.93 million. When did Telesis Bio's stock split? Telesis Bio's stock reverse split on the morning of Thursday, May 9th 2024.The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPENG (XPEV). Company Calendar Last Earnings11/08/2021Today7/23/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees200Year Founded2013Profitability EPS (Trailing Twelve Months)($20.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.72 million Net Margins-336.59% Pretax Margin-334.81% Return on EquityN/A Return on Assets-61.89% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.06 Sales & Book Value Annual Sales$225.09 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book0.01Miscellaneous Outstanding Shares1,802,000Free Float1,360,000Market Cap$1.98 thousand OptionableNo Data Beta2.43 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TBIO) was last updated on 7/23/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TBIO Stock Alerts